Ballentine Partners, LLC Gilead Sciences, Inc. Transaction History

Ballentine Partners, LLC

$5.81 Billion
Q3 2024

A detailed history of Ballentine Partners, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 19,880 shares of GILD stock, worth $1.84 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

19,880

Previous 11,429 73.94%

Holding current value

$1.84 Million

Previous $784,000 112.5%

% of portfolio

0.03%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	BUY	$66.59 - $83.99 $562,752 - $709,799	8,451 Added 73.94%	19,880 $1.67 Million
Q2 2024 Aug 06, 2024	BUY	$63.15 - $72.88 $23,870 - $27,548	378 Added 3.42%	11,429 $784,000
Q1 2024 Apr 11, 2024	SELL	$71.58 - $87.29 $292,332 - $356,492	-4,084 Reduced 26.98%	11,051 $809,000
Q4 2023 Jan 23, 2024	BUY	$73.27 - $83.09 $417,785 - $473,779	5,702 Added 60.45%	15,135 $1.23 Million
Q3 2023 Oct 19, 2023	BUY	$73.94 - $80.67 $58,708 - $64,051	794 Added 9.19%	9,433 $706,000
Q2 2023 Jul 26, 2023	BUY	$76.01 - $86.7 $111,430 - $127,102	1,466 Added 20.44%	8,639 $665,000
Q1 2023 Apr 27, 2023	BUY	$77.31 - $88.08 $38,732 - $44,128	501 Added 7.51%	7,173 $595,000
Q4 2022 Jan 27, 2023	BUY	$62.32 - $89.47 $55,464 - $79,628	890 Added 15.39%	6,672 $0
Q3 2022 Oct 26, 2022	BUY	$59.54 - $68.01 $344,260 - $393,233	5,782 New	5,782 $357,000
Q1 2022 May 05, 2022	SELL	$57.92 - $72.58 $197,159 - $247,062	-3,404 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $220,851 - $250,670	3,404 New	3,404 $248,000
Q2 2021 Aug 12, 2021	SELL	$63.47 - $69.35 $210,276 - $229,756	-3,313 Closed	0 $0
Q1 2021 May 11, 2021	BUY	$60.0 - $68.46 $198,780 - $226,807	3,313 New	3,313 $215,000
Q4 2020 Jan 25, 2021	SELL	$56.65 - $64.55 $335,991 - $382,846	-5,931 Closed	0 $0
Q3 2020 Oct 22, 2020	SELL	$62.1 - $78.08 $34,092 - $42,865	-549 Reduced 8.47%	5,931 $375,000
Q2 2020 Jul 31, 2020	SELL	$72.34 - $84.0 $5,425 - $6,300	-75 Reduced 1.14%	6,480 $498,000
Q1 2020 Apr 23, 2020	BUY	$62.63 - $80.22 $54,675 - $70,032	873 Added 15.36%	6,555 $490,000
Q4 2019 Jan 22, 2020	BUY	$61.62 - $67.78 $12,508 - $13,759	203 Added 3.71%	5,682 $369,000
Q3 2019 Oct 21, 2019	BUY	$62.51 - $69.0 $6,626 - $7,314	106 Added 1.97%	5,479 $347,000
Q2 2019 Jul 25, 2019	BUY	$61.87 - $69.38 $24,748 - $27,752	400 Added 8.04%	5,373 $363,000
Q1 2019 May 09, 2019	BUY	$62.53 - $70.05 $14,632 - $16,391	234 Added 4.94%	4,973 $323,000
Q4 2018 Feb 04, 2019	SELL	$60.54 - $79.0 $50,914 - $66,439	-841 Reduced 15.07%	4,739 $297,000
Q3 2018 Oct 30, 2018	SELL	$71.28 - $78.92 $4,276 - $4,735	-60 Reduced 1.06%	5,580 $430,000
Q2 2018 Jul 19, 2018	SELL	$64.88 - $75.68 $13,495 - $15,741	-208 Reduced 3.56%	5,640 $400,000
Q1 2018 Apr 26, 2018	SELL	$72.84 - $88.8 $55,431 - $67,576	-761 Reduced 11.51%	5,848 $442,000
Q4 2017 Feb 02, 2018	SELL	$71.15 - $83.52 $105,586 - $123,943	-1,484 Reduced 18.34%	6,609 $474,000
Q3 2017 Nov 06, 2017	BUY	$72.11 - $85.47 $583,586 - $691,708	8,093	8,093 $656,000

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ballentine Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ballentine Partners, LLC with notifications on news.

Account

Ballentine Partners, LLC Gilead Sciences, Inc. Transaction History